Related Experiment Video
Updated: May 3, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
11.3K
Pregnancy and myasthenia gravis
Continuum (Minneapolis, Minn.)
|February 5, 2014
Summary
Managing myasthenia gravis (MG) during pregnancy requires careful consideration of risks to both mother and fetus. Individualized treatment plans are essential for optimal outcomes in childbearing-aged women with MG.
Area of Science:
- Neurology
- Immunology
- Reproductive Medicine
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, with a notable incidence peak in women during childbearing years.
- Pregnancy can exacerbate MG symptoms, necessitating careful treatment strategies that consider maternal, fetal, and pregnancy health.
Observation:
- Treatment decisions for pregnant women with MG are complex, balancing disease management with potential risks.
- Observational data highlights patterns of risk to the mother, pregnancy integrity, and fetal development.
- Immunosuppressive agents carry fetal risks, and MG deterioration with respiratory compromise endangers both mother and fetus.
Findings:
- Individualized treatment is paramount, guided by MG severity, weakness patterns, comorbidities, and fetal well-being.
- Patient involvement in decision-making is crucial for successful management of MG during pregnancy.
Implications:
- Healthcare providers must be familiar with the unique considerations for managing MG in pregnant women.
- Proactive and individualized management can mitigate risks associated with MG in pregnancy for both mother and child.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:22Myasthenia Gravis ll: Pathophysiology
53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
01:15Myasthenia Gravis: Diagnostic Tests
3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
01:28Disorders of the Skeletal Muscle
2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
01:26Chemical Synapses
9.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.5K
01:26Chemical Synapses
10.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.9K